Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of REGN20566 in Adult Participants With Overweight or Obesity
This study will test a Regeneron drug called REGN20566 ("study drug") to see how safe it is and how participants with overweight or obesity respond to it.
The study will be split into two parts, Part A and Part B.
The study is looking at:
- What side effects REGN20566 might cause
- How much REGN20566 is in the blood at different times
- If the body reacts to REGN20566 in a way that may cause REGN20566 to not work as well
研究概览
详细说明
Total planned duration of trial participation for each participant (excluding screening period):
- Part A: approximately 16 weeks
- Part B: approximately 27 weeks
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Clinical Trials Administrator
- 电话号码:844-734-6643
- 邮箱:clinicaltrials@regeneron.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Has a body mass index 27-40 kg/m2, inclusive, at screening visit or prior to randomization
- Healthy volunteers with obesity
Key Exclusion Criteria:
- A self-reported change of body weight >5 kg within 90 days of screening visit
- History of type 1 or 2 diabetes, or bariatric surgery
- Hemoglobin A1c (HbA1c) ≥6.5% at the screening visit
- History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease
- Received a nutrient stimulating hormone (NuSH)-based therapy (eg, Glucagon-like peptide-1 receptor agonist [GLP-1RA]) within 6 months of the screening visit
- Planned initiation of NuSH-based therapy, bariatric surgery, or alternative procedures aimed at reducing weight or altering of body composition during the duration of the trial
- Received an anti-obesity medication within 90 days of screening visit
Note: Other protocol defined Inclusion/ Exclusion Criteria apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:A部分
|
Administered per the protocol Administered per the protocol |
|
安慰剂比较:Part B
|
Administered per the protocol Administered per the protocol |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
大体时间:Up to 16 weeks
|
Part A |
Up to 16 weeks
|
|
Severity of TEAEs
大体时间:Up to 16 weeks
|
Part A |
Up to 16 weeks
|
|
Occurrence of TEAEs
大体时间:Up to 27 weeks
|
Part B |
Up to 27 weeks
|
|
Severity of TEAEs
大体时间:Up to 27 weeks
|
Part B |
Up to 27 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Concentration of REGN20566 in serum
大体时间:Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Concentration of REGN20566 in serum
大体时间:Baseline through week 27
|
Part B |
Baseline through week 27
|
|
Occurrence of Anti-Drug Antibodies (ADA) to REGN20566
大体时间:Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Magnitude of ADA to REGN20566
大体时间:Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Occurrence of ADA to REGN20566
大体时间:Baseline through week 27
|
Part B |
Baseline through week 27
|
|
Magnitude of ADA to REGN20566
大体时间:Baseline through week 27
|
Part B |
Baseline through week 27
|
合作者和调查者
调查人员
- 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- R20566-OB-2626
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD 共享时间框架
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共享访问标准
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.